Table 3.
HRCT scores in patients with severe COVID-19 at 12 months after discharge
| HRCT normal (n=63) | HRCT abnormal (n=20) | p value | |||
|---|---|---|---|---|---|
| Age, years | 59 (51–68) | 61 (56–65) | 0·27 | ||
| Sex | |||||
| Male (n=47) | 38 (60%) | 9 (45%) | 0·23 | ||
| Female (n=36) | 25 (40%) | 11 (55%) | .. | ||
| BMI, kg/m2 | 25·3 (23·5–27·2) | 24·2 (23·3–25·7) | 0·36 | ||
| Hospitalisation | |||||
| Length of hospital stay, days | 28 (24–33) | 35 (29–37) | 0·027 | ||
| Peak CT pneumonia score during hospitalisation | 27 (24–33) | 36 (30–44) | <0·0001 | ||
| Oxygen supply | |||||
| Nasal cannula or mask (n=37) | 32 (51%) | 5 (25%) | 0·043 | ||
| HFNC or NIV (n=46) | 31 (49%) | 15 (75%) | .. | ||
| Antivirals | |||||
| Oseltamivir | |||||
| No (n=30) | 25 (40%) | 5 (25%) | 0·23 | ||
| Yes (n=53) | 38 (60%) | 15 (75%) | .. | ||
| Ganciclovir | |||||
| No (n=41) | 33 (52%) | 8 (40%) | 0·34 | ||
| Yes (n=42) | 30 (48%) | 12 (60%) | .. | ||
| Pulmonary function at month 12* | |||||
| DLCO | 90 (82–102) | 77 (66–81) | <0·0001 | ||
| FEF25–75% | 89 (76–109) | 92 (72–123) | 0·28 | ||
| FEV1:FVC | 82 (78–85) | 85 (80–86) | 0·34 | ||
| FRC | 107 (89–126) | 99 (76–106) | 0·031 | ||
| FVC | 99 (90–111) | 92 (79–100) | 0·012 | ||
| FEV1 | 97 (87–110) | 88 (75–106) | 0·054 | ||
| RV | 88 (74–102) | 75 (64–89) | 0·031 | ||
| TLC | 95 (88–104) | 88 (72–94) | 0·0074 | ||
| VC | 101 (91–112) | 92 (79–100) | 0·0037 | ||
Data are median (IQR) or n (%). BMI=body-mass index. DLCO=diffusing capacity of the lungs for carbon monoxide. FEF25–75%=forced expiratory flow between 25% and 75% of FVC. FRC=functional residual capacity. FVC=forced vital capacity. RV=residual volume. TLC=total lung capacity. VC=vital capacity. HFNC=high-flow nasal cannula. HRCT=high resolution CT. NIV=non-invasive mechanical ventilation.
*
Values are percentage of predicted value.